吉林敖东：关于控股子公司获得药品补充申请批准通知书的自愿性信息披露公告

Core Viewpoint - Jilin Aodong announced the approval of "Naloxone Hydrochloride Injection" by the National Medical Products Administration, which is a significant development for the company and its subsidiary [2] Group 1 - Jilin Aodong's subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., received the approval notification for the drug [2] - The approval is for a supplemental application for "Naloxone Hydrochloride Injection," indicating potential growth in the company's product offerings [2]